EUVIMEDEUVIMED entdecken
Open Access

Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas

Pravesh Gupta iD, Minghao Dang, Shivangi Oberai, Simona Migliozzi, Rakesh Trivedi iD, Gayatri Kumar iD, Mekenzie Peshoff, Nancy Milam, Aml Ahmed, Krishna Bojja, Tuan M Tran, Joy Gumin und 18 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Pravesh Gupta und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Glioma, Isocitrate Dehydrogenase, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: UT MDACC start-up research fund, CPRIT Single Core, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human gliomas are classified using isocitrate dehydrogenase (IDH) status as a prognosticator; however, the influence of genetic differences and treatment effects on ensuing immunity remains unclear.

Methods

In this study, we used sequential single-cell transcriptomics on 144 678 and spectral cytometry on over 2 million immune cells encompassing 48 human gliomas to decipher their immune landscape.

Results

We identified 22 distinct immune cell types that contribute to glioma immunity. Specifically, brain-resident microglia (MG) were reduced with a concomitant increase in CD8+ T lymphocytes during glioma recurrence independent of IDH status. In contrast, IDH-wild type-associated patterns, such as an abundance of antigen-presenting cell-like MG and cytotoxic CD8+ T cells, were observed. Beyond elucidating the differences in IDH, relapse, and treatment-associated immunity, we discovered novel inflammatory MG subpopulations expressing granulysin, a cytotoxic peptide that is otherwise expressed in lymphocytes only. Furthermore, we provide a robust genomic framework for defining macrophage polarization beyond M1/M2 paradigm and reference signatures of glioma-specific tumor immune microenvironment (termed GlioTIME-36) for deconvoluting transcriptomic datasets.

Conclusions

This study provides advanced optics of the human pan-glioma immune contexture as a valuable guide for translational and clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaIsocitrate DehydrogenaseBrain NeoplasmsNeoplasm Recurrence, LocalTumor MicroenvironmentHumansPrognosisBiomarkers, TumorMicrogliaSingle-Cell AnalysisLymphocytes, Tumor-InfiltratingMutationTranscriptomeCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

gliomaisocitrate dehydrogenasemicrogliatumor immune microenvironment

Substanzen

Isocitrate DehydrogenaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Neurological Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA.
  • Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Pravesh Gupta, Rakesh Trivedi, Gayatri Kumar, Jason Huse, Huma Shehwana, Frederick F Lang, Antonio Iavarone, Linghua Wang, Krishna P Bhat

Förderung

  • UT MDACC start-up research fund
  • CPRIT Single Core
  • NINDS NIH HHS
  • The University of Texas (UT) MD Anderson Cancer Center (MDACC)
  • Marnie Rose Foundation

Zitieren

APA

Gupta, P., Dang, M., Oberai, S., Migliozzi, S., Trivedi, R., Kumar, G., Peshoff, M., Milam, N., Ahmed, A., Bojja, K., Tran, T. M., Gumin, J., Kamiya-Matsuoka, C., Huse, J., Cox, K., Li, J., Shehwana, H., Sheth, S. A., Saxon, R., …, & Bhat, K. P. (2024). Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae139

Vancouver

Gupta P, Dang M, Oberai S, Migliozzi S, Trivedi R, Kumar G, et al. Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae139

BibTeX
@article{Gupta2024,
  author = {Gupta, Pravesh and Dang, Minghao and Oberai, Shivangi and Migliozzi, Simona and Trivedi, Rakesh and Kumar, Gayatri and Peshoff, Mekenzie and Milam, Nancy and Ahmed, Aml and Bojja, Krishna and Tran, Tuan M and Gumin, Joy and Kamiya-Matsuoka, Carlos and Huse, Jason and Cox, Kathryn and Li, Jianzhuo and Shehwana, Huma and Sheth, Sameer A and Saxon, Rodriguez and Baohua, Sun and Parker Kerrigan, Brittany and Maheshwari, Atul and Parra Cuentas, Edwin Roger and Navin, Nicholas E and Heimberger, Amy B and Lang, Frederick F and Iavarone, Antonio and Clise-Dwyer, Karen and Wang, Linghua and Bhat, Krishna P},
  title = {Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae139}
}
Kostenlos starten →